Cite

HARVARD Citation

    Makker, V. et al. (2022). Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Obstetrical & gynecological survey. 77 (5), pp. 275-276. [Online]. 
  
Back to record